Emergent BioSolutions Files 8-K on Financials

Ticker: EBS · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1367644

Emergent Biosolutions Inc. 8-K Filing Summary
FieldDetail
CompanyEmergent Biosolutions Inc. (EBS)
Form Type8-K
Filed DateAug 6, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, disclosure

TL;DR

Emergent BioSolutions dropped an 8-K on August 6th covering financials and other disclosures.

AI Summary

Emergent BioSolutions Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Gaithersburg, Maryland.

Why It Matters

This filing provides crucial updates on Emergent BioSolutions' financial performance and operational status, which can impact investor decisions and market perception.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can lead to significant stock price volatility.

Key Players & Entities

  • Emergent BioSolutions Inc. (company) — Registrant
  • August 6, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Gaithersburg, Maryland (location) — Principal executive offices

FAQ

What specific financial information is being disclosed in this 8-K?

The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of the financial results are not provided in the excerpt.

What is the significance of the 'Regulation FD Disclosure' item?

Regulation FD (Fair Disclosure) ensures that material non-public information is disclosed to all investors simultaneously, preventing selective disclosure.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on August 6, 2024.

Where is Emergent BioSolutions Inc. headquartered?

Emergent BioSolutions Inc.'s principal executive offices are located at 300 Professional Drive, Gaithersburg, Maryland 20879.

What is the company's Standard Industrial Classification (SIC) code?

The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 679 words · 3 min read · ~2 pages · Grade level 9.1 · Accepted 2024-08-06 16:21:53

Key Financial Figures

  • $0.001 — ange on which registered Common Stock, $0.001 oar value per share EBS New York Stock

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On August 6, 2024, Emergent BioSolutions Inc. (the "Company") issued a press release (the "Press Release") announcing its financial and operating results for the three-month period ended June 30, 2024, as well as updated guidance for 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Form 8-K") and is incorporated herein by reference.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On August 6, 2024, the Company will host a conference call to discuss its financial and operating results for the three-month period ended June 30, 2024. The Company will use presentation materials in connection with this conference call (the "Earnings Call Slides"), which will be posted on the Company's website at www.emergentbiosolutions.com . A copy of the Earnings Call Slides is furnished as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference. Information on the Company's website is not, and will not be deemed to be, a part of this Form 8-K or incorporated into any other filings the Company may make with the U.S. Securities and Exchange Commission. The information contained in Items 2.02 and 7.01 of this Form 8-K and Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions, Inc. on August 6, 2024. 99.2 Earnings Call Slides, dated August 6, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: August 6, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.